BrainStorm Cell Therapeutics (OTCQB:BCLI): To Present at Multiple Conferences

Today on Tuesday, October 08, 2013 BrainStorm Cell Therapeutics (OTCQB: BCLI) announced that the company will be presenting at multiple scientific conferences during this month and provided the brief about such conferences which include the following:

5th International Stem Cell Meeting, Israel Stem Cell Society

BrainStorm’s Chief Scientific Advisor, Professor DaniOffen, will presentat the 5th International Stem Cell Meeting during October 8th and 9th in Jerusalem. Dani’s poster presentation will be on October 8th at 17:30 as well as his oral presentation will be on October 9th around 17:15 hours. The meeting is sponsored by the Israel Stem Cell Society.

Israel Braintech 2013

Israel Braintech 2013 Meeting is scheduled on October 14th and 15th in Tel Aviv and Professor DaniOffen would be presenting on behalf of the BrainStorm Cell Therapeutics. Dani’s oral presentation will be on October 15th around 12:15 hours as a part of the session titled ‘A Spotlight on the Israeli Neuro Tech Industry’. This meeting has been sponsored by IBT (Israel Brain Technologies) which a not for profit organization to promote Israel’s neuro-technology innovation hub, inspired by the vision of Shimon Peres, an Israeli President.

Israel A.L.S Research Association

Principal Investigator of BrainStorm’s clinical trials, Professor DimitriosKarussis would be presenting at the Israel A.L.S Research Association Conference. The conference ‘From the Lab to the Clinic: An Overview of Current ALS Research in Israel’ will be organized on October 30th at Weizmann Institute of Science, Rechovot. Prof. Karussis’ oral presentation has been scheduled around 10:45.

About BrainStorm Cell Therapeutics

A biotechnology company, BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI) is a leading developer of adult stem cell technologies for neurodegenerative diseases such as Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The company holds the exclusive development and commercialization rights for its proprietary, first of its king NurOwn technology. The company’s scientific team has successfully published about 20 research publications explaining NurOwn’s in-vivo efficacy, pharmacology and mechanism of action in leading scientific journals.

Leave a Reply

Your email address will not be published. Required fields are marked *

*